Based on ICER’s evaluation, a significant reduction in the wholesale acquisition cost (WAC) of approved checkpoint inhibitors would be necessary to achieve a pre-determined value-based price benchmark.
Following a 4-week open period for public comments from patient groups, clinicians, the manufacturers of the drugs, and other stakeholders on its draft report, the Institute for Clinical and Economic Review (ICER) has released its final report assessing the comparative clinical effectiveness and value of treatments for non—small cell lung cancer (NSCLC). Based on ICER’s evaluation, a significant reduction in the wholesale acquisition cost (WAC) of approved checkpoint inhibitors would be necessary to achieve a pre-determined value-based price benchmark.
For their assessment, ICER evaluated the health and economic outcomes of tyrosine kinase inhibitors (TKIs) and programmed death 1 (PD-1) agents in the treatment of advanced NSCLC. Both TKIs and PD-1 inhibitors were evaluated in EGFR-positive (EGFR+) NSCLC, and PD-1 agents were also evaluated in EGFR-negative (EGFR—) NSCLC. The ICER report found the following:
Clinical effectiveness of agents
For patients with EGFR+ advanced NSCLC, the report found high certainty that TKI therapy is better tolerated than platinum-based chemotherapy and achieves at least equal gains in overall survival (OS), and moderate certainty that TKI therapy provides a clinically meaningful overall survival benefit. The evidence was insufficient to distinguish between the TKI drugs reviewed.
For patients with EGFR— advanced NSCLC, the report found that a substantial minority of patients respond to second-line treatment with PD-1 immunotherapies, but for those who do respond, there is high certainty of important gains in OS. The report states that existing evidence is insufficient for first-line use of PD-1 immunotherapy in NSCLC, as well as use following progression on TKI therapy.
Comparative value
The study aimed to estimate the long-term costs, outcomes, and cost-effectiveness of treatment for advanced NSCLC for the following populations:
1. First-line therapy with TKIs versus platinum-based chemotherapy for EGFR+ patients:
2. Second-line therapy with PD-1 immunotherapy versus docetaxel in EGFR— patients who progressed on a first-line chemotherapy doublet.
The report calculated the following cost-effectiveness estimates for PD-1 immunotherapies:
The report claims, however, that differences in labeled indications for each drug makes it difficult to directly compare the different drugs, along with the fact that different assays are used to test the expression of PD-1 and programmed death ligand-1.
The report states that to achieve the ICER value-based price benchmark of $100,000 to $150,000 per QALY, would need:
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More